ð¬ ç 究宀 ïŒ5ïŒæ¥æ¬äººã®ããã±ã質äžè¶³ããè¡ç³ã®ãåãç¿ããè¶³ããªãã
DïŒ7ãç©ãåç³å°¿ç ãã§ãçèãè¡ç³ã®æå€§ã®åãç¿ã§ããããšãèŠãŸãããBïŒ12ãããè¡ç³ã¬ã·ããã§ã¯ã1é£ãããããã±ã質20g以äžãç®æšã«ããŸãããBïŒ13ãçãã¬å ¥éãã§ã¯ãçèãå¢ããããã®éåãææ¡ããŸããã
ã§ãããã®åæãšãªãåããããŸã ã¡ãããšæ±ã£ãŠããŸããã§ããã
ããããæ¥æ¬äººã¯ãããã±ã質ãè¶³ããŠããã®ãïŒïŒ
çµè«ããèšããŸããè¶³ããŠããªãæ¹ãå€ãïŒïŒ
ç¹ã«é«éœ¢è
ãšè¥ã女æ§ã§æ·±å»ã§ãããããŠãç³å°¿ç
ã®æ¹ã«ãšã£ãŠãã®åé¡ã¯ãæ é€ã®è©±ãã«ãšã©ãŸããªããè¡ç³ã³ã³ãããŒã«ã®æ ¹å¹¹ã«é¢ããã
ä»åã¯ããã®ãããã±ã質äžè¶³ããè¡ç³ç®¡çã®èŠç¹ããããšããã³ã¹ãç©ã¿äžããŠæ·±æãããŸãã
æ¥æ¬äººã®ããã±ã質æåéâè¡æçãªãéæ»ãã
åœæ°å¥åº·ã»æ é€èª¿æ»ã®ããŒã¿ã远ããšãè¡æçãªäºå®ãèŠããŸãã
æ¥æ¬äººã®1æ¥ãããã®ããã±ã質æåéã¯ã1995幎ã®81.5gãããŒã¯ã«æžå°ãç¶ããçŽè¿ã§ã¯çŽ70gååŸãããã¯æŠåŸéããªã1950ã60幎代ãšãã»ãŒåãæ°Žæºã§ãã

é«åºŠçµæžæé·æã«èãåµãçä¹³ãé£ã¹ãããã«ãªã£ãŠå¢ããããã±ã質æåéãããã25å¹Žã§æ¥éã«æžã£ãŠãããããããã®æžå°ã¯ãåœããã¡ã¿ã察çããã«ããªãŒå¶éããæšé²ããææãšéãªã£ãŠããŸãã
æ°åã§èŠããäžè¶³ãã®å®æ
什å4å¹Žåœæ°å¥åº·ã»æ é€èª¿æ»ããïŒ
65æ³ä»¥äžã®äœæ é€åŸåïŒBMIâ€20ïŒã®å²åïŒ16.4%
80æ³ä»¥äžã§ã¯ç·å¥³ãšãçŽ2å²ãäœæ é€åŸå
20代女æ§ã®ããïŒBMI<18.5ïŒïŒçŽ20%
ç³å°¿ç ã匷ãçãããæ¹ïŒç·æ§18.1%ã女æ§9.1%
什å5å¹Žã®æ£è 調æ»ïŒ ç³å°¿ç ã§æ²»çãåããŠããç·æ£è æ°ã¯552äž3,000人ã
ãã®552äžäººã®äžã«ãããã±ã質ãè¶³ããŠããªãæ¹ãã©ã®ãããããã®ããæ£ç¢ºãªæ°åã¯ãªãããé«éœ¢è ãå€ãç³å°¿ç æ£è ã®éå£ã§ã¯ããäœæ é€ãšé«è¡ç³ãåæã«èµ·ããŠãããç¶æ ã¯çãããªããšãèšåºã®èæèŠãšããŠæããŠããŸãã
ãªãæžã£ãã®ãâ5ã€ã®æ§é çèŠå
ããã±ã質æåéã®æžå°ã¯ãåäººã®æå¿ã®åé¡ã§ã¯ãããŸãããç€ŸäŒæ§é ãšæ å ±ç°å¢ã®å€åãéãªã£ãçµæã§ãã
èŠå â ãé£ã¹éãããžã®éå°åå¿
2008幎ã«ã¡ã¿ãå¥èšºãå§ãŸãããã«ããªãŒãæžããããé£ã¹ãéãæžããããšããã¡ãã»ãŒãžãåºãããŸããããã®çµæããèãæžããããåµã¯1æ¥1åãŸã§ããèã£ãããã®ãæ§ããããšããé£äºå¶éãå®çã
åé¡ã¯ãã«ããªãŒãæžãããšããçã£å ã«æžãã®ãäž»èïŒèã»éã»åµïŒã ãšããããšããé£¯ãæžããã®ã¯å¿ççã«ãã€ããããèãååã«ããåµã1æ¥ããã«ãã¯æ¯èŒçãããããã
çµæãšããŠãããã±ã質ãŸã§äžç·ã«æžã£ãŠããŸã£ããã«ããªãŒã¯æžã£ããããããªãããçèãç¶æããããã®ææãæžã£ãã®ã§ãã
èŠå â¡ é«éœ¢åã«ãã飿¬²äœäžãšè²·ãç©å°é£
é«éœ¢ã«ãªããšé£æ¬²ãèœã¡ããããã¯å 霢ã«ããçççãªçŸè±¡ã§ããã¢ãã¬ãã·ã¢ã»ãªãã»ãšã€ãžã³ã°ïŒå 霢æ§é£æ¬²äœäžïŒããšåŒã°ããŸãã
é£äºéãå šäœçã«æžããç¹ã«ããã±ã質ãè¶³ããªããªããèã¯ååŒã倧å€ã§é¿ããã¡ã«ãªããäžäººæ®ããã ãšè²·ãç©ã調çã®æéãããŒãã«ã«ãªãã
ããã«ããã¬ã€ã«ã®å ¥ãå£ã«ããæ¹ã¯äœåçã«ã¹ãŒããŒãžè¡ãããšèªäœãã€ãããçµæãšããŠãæè»œã«é£ã¹ãããçæ°Žåç©äžå¿ã®é£äºïŒãã³ããã©ãããã«ããïŒã«åãã
èŠå ⢠è¥ã女æ§ã®ãããå¿åã
20代女æ§ã®ããïŒBMI<18.5ïŒã®å²åã¯çŽ20%ã5人ã«1人ã
ãã€ãšããã«ããããã±ã質æåã®äžè¶³ã¯ãå°æ¥ã®éªšéæžå°ãäœåºçäœéå ã®ãªã¹ã¯ã ãã§ãªããè¥å¹Žæããã®çèéã®å°ãªãããäžå¹Žä»¥éã®ç³å°¿ç ãªã¹ã¯ãäžããå¯èœæ§ãææããç ç©¶ãå¢ããŠããŸãã
DïŒ7ã§èŠããç©ãåç³å°¿ç ãã®èæ¯ã«ã¯ãè¥ãé ããã®æ ¢æ§çãªããã±ã質äžè¶³ãããæ¹ãå°ãªããããŸããã
èŠå â£ çæ°Žåç©äžå¿ã®é£æåãšçµæžçèŠå
ãã«ããããã³ã麺é¡ââæè»œã«é£ã¹ãããã®ã¯çæ°Žåç©äžå¿ã®é£åãã³ã³ããã§ããã³ããã«ãããæãå®ãã
ããã±ã質ãæãã«ã¯ãäž»èãçšæãããæéãšã³ã¹ãããããã åµ1ããã¯200åã¯å®ãéšé¡ã ããé¶ããè100g100åãé®1åã200åââãããæ¯é£ãšãªããšãé£è²»å šäœã«åœ±é¿ããã
EïŒ5ã§èŠããéé¢ã®çµæžçè² æ ãã®åé¡ã¯ãé£è²»ã«ãæ³¢åããŠãããæ²»çè²»ãéãæ¹ã»ã©ãé£è²»ãåãè©°ããã¡ã«ãªããããã±ãè³ªãæžããæªåŸªç°ã§ãã
èŠå †ãã³ã¬ã¹ãããŒã«ãé«ãããåµãæ§ããŠãã®èª€è§£
ãã€ãŠãåµã¯1æ¥1åãŸã§ããã³ã¬ã¹ãããŒã«ãé«ãé£åã¯æ§ããŠããšèšãããæä»£ããããŸããã
ããããçŸåšã®ãšããã³ã¹ã§ã¯ãé£äºç±æ¥ã®ã³ã¬ã¹ãããŒã«ãè¡äžã³ã¬ã¹ãããŒã«å€ã«äžãã圱é¿ã¯éå®çãšãããæ¥æ¬äººã®é£äºæååºæºïŒ2025幎çïŒã§ãã³ã¬ã¹ãããŒã«ã®æåäžéã¯èšå®ãããŠããŸããã
ã«ããããããããåµã¯æ§ããã«ããšããå€ãæ å ±ãæ ¹åŒ·ãæ®ã£ãŠãããçµæãšããŠãå®ããŠè¯è³ªãªããã±ã質æºã§ããåµãäžå¿ èŠã«é¿ããŠããæ¹ãããŸãã
ããã±ã質ãšè¡ç³ç®¡çââãªã代è¬ã®å°éå»ãæ°ã«ããã®ã
çç±â çèã¯è¡ç³ã®æå€§ã®åãç¿
é£äºã§æã£ãç³ã¯ãè¡æ¶²ãéããŠå šèº«ã«éã°ããŸãããã®ç³ãåã蟌ãæå€§ã®èåšãéªšæ ŒçïŒçèïŒã§ããäœå ã®ãããŠç³åŠçã®çŽ70ã80%ãçèãæ ã£ãŠããŸãã
çèéãæžãã°ãç³ãåã蟌ã容éãæžããè¡ç³ãäžããã«ãããªãã
ããã±ã質ãè¶³ããªã â çèãæžã â è¡ç³ã®åãç¿ãå°ãããªã â é£åŸè¡ç³ãäžããããããªã â HbA1cãæªåãã
DïŒ7ã§èŠããç©ãåç³å°¿ç ãã®æ¹ã«ããŸãã«ãã®ã¡ã«ããºã ãåããŠããŸãã

çç±â¡ ãµã«ã³ããã¢Ãç³å°¿ç ã®æªåŸªç°
ãµã«ã³ããã¢ïŒå 霢æ§çèæžå°çïŒã¯ãç³å°¿ç ã®æ¹ã«é«çã§å䜵ããŸãã
2024幎ã®Frontiers in Endocrinologyã®ã¬ãã¥ãŒã«ãããšã2åç³å°¿ç æ£è ã¯ãµã«ã³ããã¢ã®ãªã¹ã¯ãå¥åžžè ããææã«é«ãããã®åå ã¯è€åçã§ãã
ã€ã³ã¹ãªã³æµææ§ â çèã§ã®ããã±ã質åæãé»å®³
æ ¢æ§ççïŒIL-6ãTNF-αã®äžæïŒ â çèåè§£ãä¿é²
é«è¡ç³ãã®ãã® â ç³åã¹ãã¬ã¹ãç现èãå·ã€ãã
éåäžè¶³ â çèãžã®åºæ¿ãæžå°
æ«æ¢¢ç¥çµé害 â éåèœåã®äœäž
ãããŠãµã«ã³ããã¢ãé²ããšãçèéã®äœäžãããã«ã€ã³ã¹ãªã³æåæ§ãæªåãããè¡ç³ã³ã³ãããŒã«ãé£ãããªãããçèãæžãâè¡ç³ãæªåããâããã«çèãæžãããšããè² ã®ã¹ãã€ã©ã«ã§ãã

çç±â¢ ãã¢ãããªãã¯ã»ã¬ãžã¹ã¿ã³ã¹ãââé«éœ¢è ã®å£
è¥ãæ¹ãšé«éœ¢ã®æ¹ã§ã¯ãåãéã®ããã±ã質ãé£ã¹ãŠããçèã§ã®åæåå¿ãç°ãªããŸãã
é«éœ¢è ã§ã¯ãããã±ã質ãæåããŠãçèã®ããã±ã質åæïŒMPSïŒMuscle Protein SynthesisïŒãååã«åºæ¿ããã«ããçŸè±¡ãèµ·ããŸããããããã¢ãããªãã¯ã»ã¬ãžã¹ã¿ã³ã¹ïŒååæµææ§ïŒããšåŒã³ãŸãïŒAragon et al. Nutr Rev 2023ïŒã
ã€ãŸããé«éœ¢è ã¯è¥ãæ¹ãšåãéã®ããã±ã質ã§ã¯è¶³ããªããè¥ãæ¹ãããå€ããæããªããšãåãã¬ãã«ã®çèåæãç¶æã§ããªãã®ã§ãã
ã«ãããããããå®éã®æåéã¯å 霢ãšãšãã«æžã£ãŠãããéèŠãå¢ããŠããã®ã«äŸçµŠãæžããããã«ãããã±ã質ã®ã®ã£ããããçãŸããŸãã
çç±â£ ãã€ã·ã³éŸå€ââçèåæã®ãã¹ã€ããã
çèã®ããã±ã質åæãåºæ¿ããã®ã«ç¹ã«éèŠãªã¢ããé žããã€ã·ã³ã§ãããã€ã·ã³ã¯mTORC1ïŒçèåæã®ãã¹ã¿ãŒã¹ã€ããïŒã掻æ§åããéµãšãªãã¢ããé žã§ãã
ãã€ã·ã³éŸå€ïŒ 1é£ããã2.5ã3gã®ãã€ã·ã³ããçèåæãæå€§åããããã«å¿ èŠãšãããŠããŸãã
ããããé«éœ¢è ã§ã¯ã¢ãããªãã¯ã»ã¬ãžã¹ã¿ã³ã¹ã®åœ±é¿ã§ããã®éŸå€ãããã«é«ãå¯èœæ§ããããŸããã€ãŸããé«éœ¢è ã¯è¥ãæ¹ãããå€ãã®ãã€ã·ã³ã1é£ã§æãå¿ èŠãããã
ããã¯ãéãããããé£ã¹ãããšããããšã§ã¯ãªãã1é£ã®äžã«ãã€ã·ã³ãè±å¯ãªé£åã確å®ã«å ¥ãããšããããšãå ·äœçã«ã¯ãCïŒ6ã§è©³ããèŠãããã«ãåç©æ§ããã±ã質ã®ã»ãããã€ã·ã³å«æéãé«ãã
çç±â€ é£åŸã®æºè¶³æãšé£æ¬²ã³ã³ãããŒã«
ããã±ã質ã¯ãäžå€§æ é€çŽ ã®äžã§ãã¡ã°ãæºè ¹æãæç¶ããæ é€çŽ ã§ããããã¯ãé£äºèªçºæ§ç±ç£çïŒDITïŒããããã±ãè³ªã§æãé«ãïŒæåãšãã«ã®ãŒã®çŽ20ã30%ïŒããšãšãæ¶åã«æéããããããšãé¢ä¿ããŠããŸãã
ããã±ã質ãå°ãªãé£äºã¯ãé£åŸã®ç©ºè ¹æãæ©ãæ¥ãŠãéé£ãéé£ã«ã€ãªãããããã
DïŒ9ã§èŠãã16æéæé£ã§å€äžã«é£ã¹ãŠããŸããåé¡ããEïŒ3ã§èŠããå€äžã«å·èµåº«ãéããŠããŸããåé¡ããå€é£ã®ããã±ã質ãè¶³ããŠããªãããšãäžå ãããããŸããã
çç±â¥ GLP-1æä»£ã®ããã±ã質åé¡
CïŒ4ã§èŠãããã«ãGLP-1å容äœäœåè¬ã«ããäœéæžå°ã§ã¯èèªãšäžç·ã«çèãæžå°ããŸãã
STEP詊éšã®ããŒã¿ã§ã¯ãã»ãã°ã«ããã«ããäœéæžå°ã®çŽ40%ãé€èèªäœéïŒçèãå«ãïŒã®æžå°ã ã£ããšå ±åãããŠããŸãã
è¬ã§äœéãèœãšããŠããæäžã«ããã±ã質ãè¶³ããªããã°ãçèã®æžå°ãããã«å éãããææ°ã®ADAã¬ã€ãã©ã€ã³ãObesity Associationã®å£°æã§ããGLP-1䜿çšäžã®ããã±ã質ã»åŸ®éæ é€çŽ ã®å®æã¢ãã¿ãªã³ã°ã匷調ãããããã«ãªã£ãŠããŸãã
ã©ã®ãããå¿ èŠãââã¬ã€ãã©ã€ã³ã®æŽç
æ¥æ¬äººã®é£äºæååºæºïŒ2025幎çïŒãšåœéã¬ã€ãã©ã€ã³ãæŽçããŸãã
æ¥æ¬äººã®é£äºæååºæºïŒ2025幎çïŒã®æšå¥šé
æäººã®æšå¥šéïŒRDAïŒïŒ
ç·æ§ïŒ65g/æ¥ïŒ18ã64æ³ïŒã60g/æ¥ïŒ65æ³ä»¥äžïŒ
女æ§ïŒ50g/æ¥
ãã ããããã¯ãæ¬ ä¹çãäºé²ããæäœéãã§ãã æé©ãªå¥åº·ç¶æ ãç¶æããããã«å¿ èŠãªéã§ã¯ãªãã
åœéã¬ã€ãã©ã€ã³ã¯ããå€ããæšå¥š
ESPENïŒæ¬§å·èšåºæ é€ä»£è¬åŠäŒïŒExpert Group / PROT-AGE Study GroupïŒ
å¥åžžãªé«éœ¢è ïŒ1.0ã1.2 g/kg/æ¥
æ ¢æ§çŸæ£ïŒç³å°¿ç ãå«ãïŒãæããé«éœ¢è ïŒ1.2ã1.5 g/kg/æ¥
ãµã«ã³ããã¢ã®æ¹ïŒ1.6 g/kg/æ¥
äœé60kgã®æ¹ãªãã60ã96g/æ¥ã
2025幎ã®Moyama et al.ïŒNutrientsïŒã®æ¥æ¬ã§ã®ç ç©¶ïŒ 2åç³å°¿ç ã®é«éœ¢è ã«ãããŠãé£äºããã±ã質æåéãéªšæ Œçéã®æ±ºå®å åã§ããããšã暪æç ç©¶ã§ç€ºããŸãããããã¯æ¥æ¬äººã®ç³å°¿ç æ£è ã察象ãšããéèŠãªããŒã¿ã§ãã
çŸåšã®æ¥æ¬äººã®å¹³åæåéãšã®æ¯èŒ
çŸåšã®æ¥æ¬äººã®å¹³åæåéïŒçŽ70gïŒã¯ããã®ãªã®ãªè¶³ããŠããããã«èŠããŠãå®ã¯å€ãã®äººãè¶³ããŠããªããã©ã€ã³ã§ãã
ãªããå¹³å70gãã§è¶³ããªãã®ããããã¯å¹³åã«éšãããããã§ãã
è¥ãç·æ§ã¯èãããé£ã¹ãã®ã§80gä»¥äžæã£ãŠãããäžæ¹ãé«éœ¢å¥³æ§ã¯50g以äžã®æ¹ãå€ããå¹³åãããš70gã ããæ¬åœã«è¶³ããŠããªãæ¹ïŒé«éœ¢è ãè¥ã女æ§ãçµæžçã«å³ããæ¹ïŒã®å£°ã¯å¹³åã«åãããã
ã1é£20gãã®å£ââãªãåçé åã倧äºã

é£äºé åã®ç§åŠ
1æ¥ã®ããã±ã質ãåèš60gãã£ããšããŠããæ10gã»æŒ10gã»å€40gãšããåã£ãé åã§ã¯å¹çãæªãããšãããã£ãŠããŸãã
2024幎ã®LaymanïŒFrontiers in NutritionïŒã®ã¬ãã¥ãŒã«ãããšãçèã®ããã±ã質åæïŒMPSïŒã¯ãã€ã·ã³ãéŸå€ä»¥äžæåããããšã§åºæ¿ãããŸããã1é£ããã20ã30gã®ããã±ãè³ªã§æå€§åããããã以äžã¯å¹çãèœã¡ãã
ã€ãŸããå€ã«ãã«é£ãããããã3é£åçã«20gãã€æãã»ãããçèã®ç¶æã»å¢å ã«å¹æçã
åç©å®éšã§ããåãç·éã®ããã±ã質ãåçã«3é£ã«åãã矀ã¯ãå€ã«åãããçŸ€ã«æ¯ã¹ãŠåŸè¢ã®çèéãçŽ10%å€ãã£ããšããçµæãåºãŠããŸãã
æ¥æ¬äººã®é£äºé åã®åé¡
ã§ã¯ãæ¥æ¬äººã®ããã±ã質æåã¯ã©ã®é£äºã§äžè¶³ããŠãããã
å§åçã«æé£ã§ãã
ããŒã¹ããšã³ãŒããŒã ãããã«ãã1åãèåãã³ãã·ãªã¢ã«ãšçä¹³ãââãããã®æé£ã®ããã±ã質ã¯5ã10gçšåºŠã20gã«ã¯å šç¶å±ããªãã
æŒé£ããã³ã³ããã®ãã«ãã2åã§ã¯çŽ7gãã«ãã麺ã§ã¯çŽ8gã
çµæãšããŠãæã»æŒã¯ããã±ã質ãäžè¶³ããå€ã«ãŸãšããŠæããã¿ãŒã³ã«ãªã£ãŠãããããã¯çèåæã®èгç¹ããã¯éå¹çã
BïŒ12ã®ãã¿ãŒã³BãåµïŒçŽè±ã¹ããŒãå®é£ããããŸãã«ãã®åé¡ãžã®çãã§ããåµ2åïŒ14gïŒïŒçŽè±ïŒ7gïŒïŒ21gã調çæé3åã
ææ°ã®ç¥èŠïŒãæé£ã®ããã±ã質ãã®éèŠæ§
Laymanã®ã¬ãã¥ãŒã§ã¯ãæé£ã«ããã±ã質ãå¢ããããšïŒããããããããã€ã³ã»ããã³ãããŒãã£ã³ã°ãïŒãã1æ¥ã®çèåæãšäœçµæã®æ¹åã«æã广çã§ãããšçµè«ã¥ããŠããŸãã
çç±ã¯ãå€éã®çµ¶é£åŸãæã¯çèãæãããã±ã質ãå¿ èŠãšããŠããç¶æ ïŒç°åãé²ãã ç¶æ ïŒã ãããããã«ãã£ããããã±ã質ãå ¥ããããšã§ãç°åããååãžã®ã¹ã€ãããæ©ãåãæ¿ããããã
èšåºã§ããèŠããããã±ã質äžè¶³ã®ãµã€ã³ã
倿¥ã§ä»¥äžã®ãããªæ¹ã蚺ããšãããã±ã質äžè¶³ãçããŸãã
ãµã€ã³â HbA1cãé£äºã»éåé 匵ã£ãŠããã®ã«äžãããªã
é£äºãèŠçŽãããæ©ããŠãããè¬ã飲ãã§ãããã§ãHbA1cãæ¹åããªãã
ããããæ¹ã®é£äºå 容ã詳ããèããšãã«ããªãŒã¯æžãããŠãããããã±ã質ãäžç·ã«æžã£ãŠããã±ãŒã¹ãå€ããã«ããªãŒå¶éãçèã®æžå°ãæããã€ã³ã¹ãªã³æåæ§ãããã«æªåããŠããå¯èœæ§ãããã
ãµã€ã³â¡ äœéã¯æžã£ããäœèèªçã¯å€ãããªã
ãç©ããã®ã«ããè ¹ã®èèªãæžã£ãŠãªããââããã¯çèãæžã£ãŠèèªãæ®ã£ãŠããç¶æ ãããããããµã«ã³ããã¢è¥æºãã®å ¥ãå£ã
äœéèšã®æ°åã ãã§å€æãããäœçµæïŒçèéãšèèªéã®ãã©ã³ã¹ïŒãèŠãå¿ èŠãããã
ãµã€ã³â¢ å·ã®æ²»ããé ã
ããã±ã質ã¯çµç¹ä¿®åŸ©ã®ææãäžè¶³ãããšå·ã®æ²»ããé ããªããç³å°¿ç ã®æ¹ã¯è¡æµé害ããããããããã±ã質äžè¶³ïŒè¡æµé害ã®ããã«ãã³ãã§åµå·æ²»çãèããé å»¶ããã
ãµã€ã³â£ ææçã«ãããããã
å ç«ã°ãããªã³ïŒæäœïŒã¯ããã±ã質ã§ã§ããŠãããããã±ã質ãäžè¶³ãããšå ç«æ©èœãäœäžãããç³å°¿ç ã®æ¹ã¯é«è¡ç³ã«ããå ç«æ©èœäœäžããããããææçãªã¹ã¯ãããã«äžããã
ç³å°¿ç ã®æ¹ãç¹ã«æ³šæãã¹ãããš
è æ©èœãäœäžããŠããæ¹ââããã£ãšé£ã¹ããããå±éºãªå Žå
ããããã¡ã°ã倧äºãªæ³šæç¹ã§ãã
ããã±ã質ã®éå°æåã¯è èã«è² æ ããããå¯èœæ§ããããŸããç¹ã«eGFRïŒæšç®ç³žçäœæ¿ŸééïŒãäœäžããŠããæ¹ã¯ã䞻治å»ãšçžè«ããŠããã±ã質ã®é©æ£éãæ±ºããŠãã ããã
ç³å°¿ç æ§è çã®ã¹ããŒãžã«ãã£ãŠã¯ãããã±ã質å¶éãå¿ èŠãªå ŽåããããŸãã
ã¹ããŒãž1ã2ïŒeGFR 60以äžïŒïŒ éåžžãããå€ãïŒ1.0ã1.2g/kg/æ¥ïŒã§åé¡ãªãããšãå€ã
ã¹ããŒãž3ïŒeGFR 30ã59ïŒïŒ 䞻治å»ã®å€æã0.8ã1.0g/kg/æ¥çšåºŠã«å¶éãããããšããã
ã¹ããŒãž4ã5ïŒeGFR 30æªæºïŒïŒ ããã±ã質å¶éãå¿ èŠã0.6ã0.8g/kg/æ¥
ãããã±ã質ã¯å€ããã°å€ãã»ã©ãããã§ã¯ãããŸããã èªåã®è æ©èœã«åã£ãéãç¥ãããšã倧äºã§ããè èå ç§ãšé£æºããŠããå Žåã¯ãå¿ ããã¡ãã®æç€ºã«åŸã£ãŠãã ããã
é«éœ¢ã®æ¹ââé£ã¹ãããŠãé£ã¹ãããªããžã¬ã³ã
ãã¬ã€ã«äºé²ã®ããã«ããã±ã質ãå¢ããã¹ãã ãã飿¬²ãèœã¡ãŠé£ã¹ãããªãããã®ãžã¬ã³ãã¯èšåºã§ããèŠãŸãã
察çãšããŠæå¹ãªã®ã¯ãéãå¢ãããã®ã§ã¯ãªãã質ãäžãããããšïŒ
å°éã§é«ããã±ãã®é£åãéžã¶ïŒ åµ1åïŒ7gããšãŒã°ã«ã100gïŒ4gãããŒãº1åãïŒ7gããã猶1猶ïŒ16g
éé£ã§ããã±ã質ãè£ãïŒ ãã§åµããããã€ã³ãšãŒã°ã«ããããã
ãã¡ããè¶³ããã§åºäžãããïŒ å³åæ±ã«è±è ãè¶³ããã飯ã«çŽè±ããããããµã©ãã«ãããè¶³ã
çµå£æ é€è£å©é£åïŒONSïŒã®æŽ»çšïŒ ãšã³ã·ã¥ã¢ãã¡ã€ãã©ã³ã¹ãªã©ã®æ é€ããªã³ã¯ãé£äºéãæ¥µç«¯ã«å°ãªãæ¹ã«ã¯æå¹
ã¡ããã«ãã³äœ¿çšäžã®æ¹ââãã¿ãã³B12ã«æ³šæ
ã¡ããã«ãã³ã¯ç³å°¿ç ã®ç¬¬äžéžæè¬ã§ãããé·æäœ¿çšã§ãã¿ãã³B12ã®åžåãäœäžããããšãç¥ãããŠããŸãã
ãã¿ãã³B12ã¯äž»ã«åç©æ§é£åã«å«ãŸãããããã±ã質æåãäžè¶³ããŠããæ¹ã§ããã€ã¡ããã«ãã³ãé·æäœ¿çšããŠããæ¹ã¯ãB12æ¬ ä¹ã®ãªã¹ã¯ãäºéã«ããã£ãŠããå¯èœæ§ããããŸãã
宿çãªB12ã®ãã§ãã¯ã䞻治å»ã«äŸé ŒããŠãã ããã
å®è·µã«èœãšãââã1é£20gããç¡çãªãéæãã

æé£ã®ããã±ã質ãå¢ããïŒæåªå ïŒ
åµ2åïŒçŽè±ïŒ21gïŒèª¿ç3åïŒââããããã¡ã°ãçŸå®çãBïŒ12ã®ãã¿ãŒã³Bãã®ãã®ã
ããããé¢åãªæ¹ïŒ ã³ã³ããã§ãã§åµ1åïŒçä¹³200mlïŒ14gãè¶³ããªããã©ã0gããã¯ããã«ããã
æŒé£ã«ããã±ã質ãè¶³ã
ã³ã³ããå©çšïŒ ãã«ãã1åïŒãµã©ãããã³ïŒ25gïŒïŒå³åæ±ïŒåèš30g以äžãBïŒ11ã®ãã¿ãŒã³Aãã®ãã®ã
å€é£ïŒ å®é£å±ã§çŒãéå®é£ãéžã¶ãç䞌ãªããçç¿ïŒã飯å°ãã§äž»èã®ããã±ã質ã確ä¿ã
å€é£ã¯ãè¶³ããŠãããããšãå€ã
æ¥æ¬äººã®å€é£ã¯æ¯èŒçããã±ã質ãå€ãïŒèãéã®äž»èãããïŒãåé¡ã¯æãšæŒãå€é£ããã以äžå¢ããå¿ èŠã¯ãªããæãšæŒã«åé ããã®ãæãå¹ççã
鱿«ã®ãäœã眮ããã§ããŒãã«ãäžãã
BïŒ12ã§ç޹ä»ãããèžãé¶ã®äœã眮ãããããã§åµ5åãŸãšãäœããã鱿«ã«30åã ã䜿ãã°ãå¹³æ¥ã®æé£ã»æŒé£ã®ããã±ã質確ä¿ããã£ãšæ¥œã«ãªããŸãã
è¡ç³ãªã¿ã¯çãŸãšã
æ¥æ¬äººã®ããã±ã質æåéã¯1995幎ã®81.5gããçŽ70gãžæžå°ã1950幎代ãšåæ°Žæº
èæ¯ã«ã¯ã¡ã¿ã察çã®éå°åå¿ãé«éœ¢åãããå¿åãçæ°Žåç©åéãçµæžçèŠå ããã
ããã±ã質äžè¶³ã¯ãçèæžå°âè¡ç³ã®åãç¿çž®å°âé£åŸè¡ç³äžæãã®æªåŸªç°ãæã
ãµã«ã³ããã¢ãšç³å°¿ç ã¯äºããæªåãããè² ã®ã¹ãã€ã©ã«
é«éœ¢è ã¯ãã¢ãããªãã¯ã»ã¬ãžã¹ã¿ã³ã¹ãã®ãããè¥ãæ¹ããå€ãã®ããã±ã質ãå¿ èŠ
ESPEN/PROT-AGEã¬ã€ãã©ã€ã³ïŒæ ¢æ§çŸæ£è ã¯1.2ã1.5g/kg/æ¥ãæšå¥š
æ¥æ¬ã®2åç³å°¿ç é«éœ¢è ã§ããã±ã質æåéãéªšæ Œçéã®æ±ºå®å åïŒMoyama et al. 2025ïŒ
1é£ããã20gã®åçé åããå€ã«ãŸãšããŠé£ã¹ãããçèç¶æã«å¹æçïŒLayman 2024ïŒ
ãã¡ã°ãè¶³ããªãã®ã¯ãæé£ããåµ2åïŒçŽè±ã§21gïŒ3åã§è§£æ±º
GLP-1䜿çšäžã¯ããã±ã質ã¢ãã¿ãªã³ã°ãç¹ã«éèŠïŒADA 2026, Obesity AssociationïŒ
ãã ãè æ©èœäœäžãããæ¹ã¯éå°æåã«æ³šæã䞻治å»ãšçžè«ã
åèæ å ±
ã»åçåŽåçãåœæ°å¥åº·ã»æ é€èª¿æ»ãïŒä»€å4幎ã»5幎ïŒ
ã»åçåŽåçãæ¥æ¬äººã®é£äºæååºæºïŒ2025幎çïŒãããã±ã質
ã»Deutz NEP et al. ESPEN Expert Group: Protein intake and exercise for optimal muscle function with aging. Clin Nutr 2014
ã»Bauer J et al. PROT-AGE Study Group: Evidence-based recommendations for optimal dietary protein intake in older people. JAMDA 2013
ã»Layman DK. Impacts of protein quantity and distribution on body composition. Front Nutr 2024
ã»Aragon AA et al. Age-related muscle anabolic resistance: Inevitable or preventable? Nutr Rev 2023
ã»Moyama S et al. Dietary Protein Intake Is a Determining Factor for Skeletal Muscle Mass in Japanese Older People with Type 2 Diabetes. Nutrients 2025
ã»Frontiers in Endocrinology 2023: Pathogenesis and comprehensive treatment strategies of sarcopenia in elderly patients with T2DM
ã»ADA Standards of Care 2026
ð¬ æ¬¡ã®ç 究宀 â ïŒ6ãæ€ç©æ§ vs åç©æ§ããã±ã質ã
ð å
·äœçãªã¬ã·ã â å®è·µãŒãïŒ12ãããè¡ç³ã¬ã·ãã
â ïž ç©ãåã®æ¹ã¯ â ããã¶ä»£è¬ã®ããïŒ7
ð çãã¬ã®å§ãæ¹ â å®è·µãŒãïŒ13
ð« å
šã³ã³ãã³ã â ãã®åŠæ ¡ã®æ©ãæ¹
ð§ââïž æ¥ã
ã®è¡ç³ãã¿ â XïŒ@medinotoïŒ
â»ãã®èšäºã¯äžè¬çãªæ å ±æäŸãç®çãšããŠããŸããããã±ã質ã®é©æ£éã¯è æ©èœãªã©å人ã®ç¶æ ã«ãã£ãŠç°ãªããŸãã䞻治å»ã»ç®¡çæ é€å£«ã«ãçžè«ãã ããã
ãããªãšæã£ããå¿æŽãããïŒ
åå ããŠãã ãã£ãŠããããšãããããŸãããããã¯ãã®ãåŠã³ã®å Žããè²ãŠãããã®å¿æŽãšããŠããšãŠãå¬ããã§ããããå¯èœãªããã©ããè¯ãã£ããããæ¬¡ã«ç¥ãããããŒãããäžèšã³ã¡ã³ãã§æããŠãã ãããæ¬¡ã®èšäºã«åæ ããŸãããããã¯ç¡çã®ãªãç¯å²ã§å€§äžå€«ã§ãã